Professor Igor Bartenjev, MD, PhD, Department of Dermatovenerology, Medical faculty, University of Ljubljana, Pod kostanji 4, 1000 Ljubljana, Slovenia;
Acta Dermatovenerol Croat. 2020 Jul;28(1):34-37.
Topical imiquimod is a medication approved for the treatment of external genital and perianal warts, actinic keratosis, and superficial basal cell carcinoma. There have also been reports of its successful use in patients with lentigo maligna melanoma in situ. An 80-year-old female patient was diagnosed with lentigo maligna melanoma in situ which was then surgically removed. After several recurrences, nonsurgical treatment using topical 5% imiquimod was introduced. At 9-month follow-up the skin was completely healed with no evidence of cancer recurrence. In select cases, topical imiquimod seems to be an effective alternative to surgical treatment of melanoma in situ (MIS). Further studies are necessary to assess the successfulness of this treatment method.
局部咪喹莫特是一种已被批准用于治疗外阴和肛门生殖器疣、光化性角化病和浅表基底细胞癌的药物。也有报道称，它对原位恶性黑素瘤患者也有成功的治疗作用。一名 80 岁的女性患者被诊断为原位恶性黑素瘤，随后进行了手术切除。在几次复发后，采用局部 5%咪喹莫特进行非手术治疗。在 9 个月的随访中，皮肤完全愈合，没有癌症复发的迹象。在某些情况下，局部咪喹莫特似乎是原位黑素瘤（MIS）手术治疗的有效替代方法。需要进一步的研究来评估这种治疗方法的成功。
